Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported business highlights and third quarter 2024 financial results. "This is ...
Sangamo engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1/2 STAAR study showing encouraging safety and efficacy data ...
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding ...
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement ...
Another report 2 from the World Health Organization estimates that at least ... In a recent discussion hosted by Nutan ...
Sangamo engaged with the FDA on alternative pathways to potential approval following analysis of clinical data from the Phase 1/2 STAAR study showing encouraging safety and efficacy data, including ...
Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings ... to the $8 million or 10% increase in ICL sales and $0.2 million decrease in other products. Constant currency net ...
STAAR Surgical Company beats earnings expectations ... attributable to the $8 million or 10% increase in ICL sales and $0.2 million decrease in other products. Constant currency net sales for ...
(Instead of: APAC sales growth of 4% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%). Staar Surgical (STAA) delivered earnings and revenue surprises of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback